ELDN
EledonFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-20
Current thesis
Bull case assumes positive clinical signals from FB-401 and either a partnering deal or non-dilutive capital within 12 months, driving re-rating and improved liquidity.
Posture
Defensive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta -4.2.
What can break
Bear case assumes clinical setbacks or the need for a significant dilutive financing round within 12 months that materially increases share count and compresses the price.
Momentum
64
Value
41
Sentiment
0
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $0.08 · Bull $0.16 · Bear $0.04
Data freshness
Prices
As of 2026-07-20
Fundamentals
As of 2026-07-20 • Vendor: Data Vendor v1
Scores
As of 2026-07-20 • Model: HYBRID_IC_RP
AI Memo
As of 2025-12-08 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-07-20
Investment thesis
As of 2026-07-20
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Target $9.00
Why
Momentum64 · Δ7d -4.2
Value41 · Δ7d +0.0
Sentiment0 · Δ7d 0.0
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Momentum · See technicals
Momentum
64
26% active weight
Current posture
7d trendSoftening
Δ7d
-4.2
Δ21d
-26.3
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
+0.0
Δ21d
-0.1
Sentiment
0
34% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
0.0
Why this grade
Composite grade F. Momentum 64.0 / Value 41.1 / Sentiment 0.0
Fundamentals (TTM)As of 2026-07-20
Fundamentals (TTM)
As of 2026-07-20
Market Cap
$297.95M
Beta
0.89
Shares Out
77.19M
P/E (TTM) · Derived
-6.9
P/S (TTM)
-
P/FCF (TTM) · Derived
-4.79
Rev YoY
-
EPS YoY
+312.2%
Gross Margin
-
Op Margin
-
Net Debt
-$132.7M
Current Ratio
8.44
As of 2026-07-20 • Updated nightlySource: Internal modelMethodology